LQDALiquidia Corporation

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+141.5% YoY

Gross Profit

$8M85.4% margin

Operating Income

-$38M-424.4% margin

Net Income

-$42M-470.5% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+183.2%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$257M

Total Liabilities

$242M

Stockholders' Equity

$15M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$4M	+141.5%
Gross Profit	$8M	$2M	+248.3%
Operating Income	-$38M	-$27M	-37.9%
Net Income	-$42M	-$28M	-48.8%

Revenue Segments

Product

$7M74%

Service

$2M26%

LQDA Q2 2025 Earnings — Liquidia Corporation Revenue & Financial Results | Market Cap Arena